Conjugated Estrogens Articles
Duramed Takes New Tack In Premarin Bid
7 August 1997
Barr Labs Launches First Generic Warfarin In USA
31 July 1997
Duramed Takes On FDA Over Generic Premarin Block
31 July 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Duramed Files Premarin Appeal
19 June 1997
Raloxifene Data Lives Up To Expectations
12 June 1997
New York Stock Comment
12 May 1997
FDA Rejects Generic Premarin Challenge
12 May 1997
Barr & Wyeth Ayerst's Premarin Battle
25 November 1996
NEW YORK STOCK COMMENT
18 November 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Generic Premarin
20 May 1996
Strong Growth At AHP At Start Of 1996
6 May 1996
New Turn In Generic Premarin Dispute
29 April 1996
Premarin Heads Top-10 Prescription Drugs
1 April 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
Metra Biosystems/Wyeth Ayerst osteoporosis deal
4 December 1995
Duramed 3rd quarter results
27 November 1995
Duramed Move In Premarin Fracas
16 October 1995
Wyeth-Ayerst's Cordarone IV Approved In USA
14 August 1995
FDA Panel Verdict On Premarin Inconclusive
7 August 1995
FDA Hearing To Determine Generic Premarin Fate
31 July 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Merck's Fosamax Nears Market In USA
24 July 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Solid 2nd Qtr Earnings Growth For US Drugmakers
17 July 1995
Wyeth Acts To Protect Premarin Business
5 June 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
IMS Studies US Retail Drug Payments
16 January 1995
Prempro Approved In USA
9 January 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
USA's Top-Selling Drugs In 1993
24 October 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
RECORD RESULTS FOR AMERICAN HOME
25 April 1994
B-MS LAUNCH IN USA
28 March 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
RAPID GROWTH FOR WORLD ENDOCRINEs
25 October 1993
R&D INVESTMENTS BY US GENERICS MAKERS
28 June 1993
WYETH-AYERST WIDENS GENERIC LINE
17 May 1993
ELI LILLY'S RALOXIFENE: PHASE II RESULTS
26 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
WORLD ENDOCRINE MARKET AND FORECASTS
29 March 1993
WYETH TO GET DUTCH MOH COMPENSATION
1 February 1993
AMERICAN HOME: FINALLY A PHARMA COMPANY
7 December 1992
US/CANADA DRUG PRICE STUDY "MISLEADING"
2 November 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
Duramed agreement
6 July 1992
US FDA ABANDONS COMPANY ALERT LIST
29 June 1992
WYETH LOSES ROUND IN GENERICS BATTLE
15 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
AMERICAN HOME ISA "STRONG BUY"
18 May 1992
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
